Cyrus Harmon sold $148k of OLMA
director at Olema Pharmaceuticals, Inc.. 16,393 shares at an average of $9.03, traded Dec 10, 2024, filed Dec 11, 2024.
Score components
- +15RoleDirector
- +11Trade size$148k at market
- 0Share of holdings soldSold 2.1% of holdings
- +15Cluster6 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-029028, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 9, 2024 | AGrant or award Common Stock | +29,250 | $0.00 | $0 | 780,533 | Dec 11, 2024 |
| Dec 10, 2024 | SOpen-market sale Common Stock | -8,256 | $9.37 | $77k | 772,277 | Dec 11, 2024 |
| Dec 11, 2024 | SOpen-market sale Common Stock | -7,958 | $8.66 | $69k | 764,319 | Dec 11, 2024 |
| Dec 11, 2024 | SOpen-market sale Common Stock | -179 | $9.39 | $1,681 | 764,140 | Dec 11, 2024 |
Related signals
Other insiders at Olema Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 32Weak | OLMAbuy Olema Pharmaceuticals, Inc. | Bain Capital Life Sciences Investors, LLC owner | $1.7M 300,000 shares | +4% | |
| 48Moderate | OLMAbuy Olema Pharmaceuticals, Inc. | G. Walmsley Graham director | $4.7M 700,761 shares | - | |
| 75Notable | Olema Pharmaceuticals, Inc. | G. Walmsley Graham director | $4.7M 700,761 shares | -100% | |
| 55Moderate | OLMAbuy Olema Pharmaceuticals, Inc. | G. Walmsley Graham director | $4.7M 700,761 shares | +99% | |
| 75Notable | Olema Pharmaceuticals, Inc. | G. Walmsley Graham director | $4.7M 700,761 shares | -100% | |
| 75Notable | Olema Pharmaceuticals, Inc. | Sean Bohen PRESIDENT AND CEO | $986k 109,502 shares | -31% | |
| 44Moderate | Olema Pharmaceuticals, Inc. | Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. | $317k 35,159 shares | -6% | |
| 43Moderate | Olema Pharmaceuticals, Inc. | David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | $235k 26,066 shares | -4% | |
| 48Moderate | Olema Pharmaceuticals, Inc. | Naseem Zojwalla CHIEF MEDICAL OFFICER | $250k 27,805 shares | -19% | |
| 60Notable | OLMAsell Olema Pharmaceuticals, Inc. | G. Walmsley Graham director | $17M 1,175,000 shares | -84% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.